Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group
Authors:
- 1 November 2000
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 14 (11) , 1939-1943
Abstract
The medium-risk B cell precursor acute lymphoblastic leukemia (ALL) accounts for 50–60% of total childhood ALL and comprises the largest number of relapses still unpredictable with diagnostic criteria. To evaluate the prognostic impact of minimal residual disease (MRD) in this specific group, a case control study was performed in patients classified and treated as medium (or intermediate)-risk according to the criteria of national studies (ALL-BFM 90, DCLSG protocol ALL-8, AIEOP-ALL 91), which includes a good day 7 treatment response. Standardized polymerase chain reaction (PCR) analysis of patient-specific immunoglobulin and T cell receptor gene (TCR) rearrangements were used as targets for semi-quantitative estimation of MRD levels: ⩾10−2, 10−3, ⩽10−4. Twenty-nine relapsing ALL patients were matched with the same number of controls by using white blood cell count (WBC), age, sex, and time in first complete remission, as matching factors. MRD was evaluated at time-point 1 (end of protocol Ia of induction treatment, ie 6 weeks from diagnosis) and time-point 2 (before consolidation treatment, ie 3 months from diagnosis). MRD-based high risk patients (⩾10−3 at both time-points) were more frequently present in the relapsed cases than in controls (14 vs 2), while MRD-based low risk patients (MRD negative at both time-points) (1 vs 18) showed the opposite distribution. MRD-based high risk cases experienced a significantly higher relapse rate than all other patients, according to the estimated seven-fold increase in the odds of failure, and a much higher rate than MRD-based low risk patients (OR = 35.7; P = 0.003). Using the Cox model, the prediction of the relapse-free interval at 4 years was 44.7%, 76.4% and 97.7% according to the different MRD categories. MRD-based risk group classification demonstrate their clinical relevance within the medium-risk B cell precursor ALL which account for the largest number of unpredictable relapses, despite the current knowledge about clinical and biological characteristics at diagnosis. Therefore, MRD detection during the first 3 months of follow-up can provide the tools to target more intensive therapy to those patients at true risk of relapse.Keywords
This publication has 21 references indexed in Scilit:
- Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemiaLeukemia, 1999
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemiaThe Lancet, 1998
- Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual diseaseLeukemia, 1997
- Early response to therapy and outcome in childhood acute lymphoblastic leukemiaCancer, 1997
- Cytoreduction and prognosis in childhood acute lymphoblastic leukemia.Journal of Clinical Oncology, 1996
- Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised childrenThe Lancet, 1996
- Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.Journal of Clinical Oncology, 1996
- Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of inductionThe Lancet, 1994